SCHEMBL6522359

SCHEMBL6522359

Cc1[nH]nc2c1c(=O)n(CCCNC(=O)c1ccccc1Cl)c1ccccc21

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 3/20 0.50
AURKA O14965 1/20 0.50
KDR P35968 1/20 0.50
AURKB Q96GD4 1/20 0.50
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
TDP1 Q9NUW8 2/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C9 P11712 1/20 0.44
BRD4 O60885 1/20 0.41
SLC6A4 P31645 1/20 0.41
NPC1 O15118 2/20 0.40
POLB P06746 1/20 0.40
SMYD2 Q9NRG4 1/20 0.40
CNR2 P34972 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6523103 0.87 CHEK1 (0.55) CHEK1AURKAKDRAURKBTDP1
SCHEMBL6519817 0.86 CHEK1 (0.50) CHEK1AURKAKDRAURKBHPGD
SCHEMBL6510076 0.85 AURKA (0.57) CHEK1AURKAKDRAURKBBRD4
SCHEMBL6515699 0.85 CHEK1 (0.55) CHEK1AURKAKDRAURKBMEN1
SCHEMBL6521705 0.84 AURKA (0.51) CHEK1AURKAKDRAURKBTDP1
SCHEMBL6519036 0.84 CHEK1 (0.47) CHEK1AURKAKDRAURKBKMT2A
SCHEMBL6517752 0.83 AURKA (0.50) CHEK1AURKAKDRAURKBMEN1
SCHEMBL6523094 0.83 CHEK1 (0.47) CHEK1AURKAKDRAURKBTP53
SCHEMBL6508848 0.83 AURKA (0.54) CHEK1AURKAKDRAURKBKMT2A
SCHEMBL6513140 0.83 AURKA (0.49) CHEK1AURKAKDRAURKBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885AURKA 78/4885KDR 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.